WHO Drug Information Vol. 13, No. 4, 1999
(1999; 83 pages) Voir le document au format PDF
Table des matières
Ouvrir ce répertoire et afficher son contenuGeneral Policy Issues
Ouvrir ce répertoire et afficher son contenuReports on Individual Drugs
Ouvrir ce répertoire et afficher son contenuCurrent Topics
Ouvrir ce répertoire et afficher son contenuVaccines and Biomedicines
Fermer ce répertoireRegulatory and Safety Matters
Afficher le documentLeflunomide: pancytopenia and skin reactions
Afficher le documentDidanosine and pancreatitis
Afficher le documentSertraline for post-traumatic stress disorder
Afficher le documentPemoline withdrawal following liver complications
Afficher le documentLevetiracetam: new drug for epilepsy
Afficher le documentMethotrexate: monitoring essential
Afficher le documentMethotrexate: care in prescribing
Afficher le documentGrepafloxacin withdrawal: severe cardiovascular events
Afficher le documentReteplase incompatible with heparin
Afficher le documentPostmarketing system to be revised
Afficher le documentAbacavir: hypersensitivity reactions
Afficher le documentInitiative to curb illegal sale of drugs over the Internet
Afficher le documentUnapproved HIV test kits available on the Internet
Afficher le documentV-King®: unapproved use of sildenafil
Afficher le documentMiralex®: undeclared corticosteroid
Afficher le documentRules for dietary supplements finalized
Ouvrir ce répertoire et afficher son contenuATC/DDD Classification
Ouvrir ce répertoire et afficher son contenuEssential Drugs
Afficher le documentInternational Nonproprietary Names for Pharmaceutical Substances (INN)
Afficher le documentSelected WHO Publications of Related Interest
 

Rules for dietary supplements finalized

United States of America — The Food and Drug Administration has published its final rule defining the types of statements that can be made concerning the effect of a dietary supplement on the structure or function of the body. This rule describes how disease claims can be distinguished from structure/function claims. Although this rule will not affect the availability of dietary supplements, it may affect whether certain claims can be made and will result in some labelling changes.

As an example, the rule precludes express and implied disease claims, but permits claims that do not relate to disease. Serious conditions such as ageing, pregnancy, and menopause will continue to be treated as diseases.

Publication of the rule is an important part of the FDA's overall dietary supplement strategy aimed at providing consumers with a high level of confidence in the safety, composition and labelling of dietary supplements.

Reference: FDA Talk Paper, T00-1, 2000.

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013